Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + gemcitabine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Temsirolimus + gemcitabine is a combination therapy regimen consisting of the mTOR inhibitor temsirolimus and the antimetabolite gemcitabine. Temsirolimus, a derivative of sirolimus, binds to the intracellular protein FKBP-12, and the resulting complex inhibits the activity of mTOR Complex 1 (mTORC1), thereby blocking downstream signaling pathways essential for cell cycle progression and angiogenesis. Gemcitabine is a nucleoside analog that is phosphorylated intracellularly into active metabolites; these metabolites inhibit DNA synthesis by competing with deoxycytidine triphosphate for incorporation into DNA and by inhibiting ribonucleotide reductase, leading to a depletion of deoxynucleotide pools. This combination was specifically investigated in a Phase 1 dose-escalation trial led by Massachusetts General Hospital for the treatment of previously untreated metastatic pancreatic adenocarcinoma.
- Brand names
- ToriselGemzar
- Other names
- temsirolimus and gemcitabine combination
02
Targets
DNARNR (Ribonucleotide reductase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on temsirolimus + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + gemcitabine.